GRIFOLS, S.A. |
Market Closed -
Other stock markets
|
After market 01:31:46 pm | |||
| 8.45 EUR | +0.76% |
|
8.618 | +1.99% |
Presenter SpeechNuria Lapeña (Executives)Hello, everyone, and welcome to the Grifols Second Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
8.386
EUR
Average target price
18.03
EUR
Spread / Average Target
+115.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.33% | 5.41B | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -14.30% | 15.36B | |
| -8.82% | 11.95B | |
| -15.86% | 11.6B | |
| -43.00% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B |
- Stock Market
- Equities
- GRF Stock
- News Grifols, S.A.
- Transcript : Grifols, S.A., Q2 2023 Earnings Call, Jul 27, 2023
